Peptide · Fact sheet
Exenatide
Also known as Byetta · Bydureon · exendin-4
Exenatide is FDA approved for type 2 diabetes, not Parkinson disease. A larger Phase 3 Parkinson trial found no evidence that extended-release exenatide slowed motor progression, despite an earlier positive trial.
What is Exenatide?
Exenatide is a peptide GLP-1 receptor agonist based on exendin-4, a peptide first identified in Gila monster saliva.
Its glucose-lowering approval and its experimental neurodegeneration hypothesis are separate evidence categories.
Benefits people look for
An earlier randomized Parkinson trial reported a persistent motor-score difference after a washout period, raising disease-modification interest.
The subsequent larger Phase 3 study did not confirm benefit, showing why replication outweighs a compelling mechanism or single positive trial.
What the evidence supports
- Approved diabetes benefits are established within labeled use.
- An earlier Parkinson trial generated a motor signal, but the larger Phase 3 trial found no meaningful benefit on the primary motor endpoint.
All research areas
- Type 2 diabetes
- Parkinson disease progression
- Motor function
- GLP-1 neurobiology
- Parkinson disease and neuroprotection research
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
No attributable personal reports are summarized here yet. The benefits above describe research interests; the side effects below come from the cited medical sources.
We do not fill this gap with unsourced testimonials or estimated success rates.
Side effects & risks
- Current labeling describes pancreatitis, kidney injury, severe gastrointestinal disease, hypersensitivity, gallbladder disease, and rare immune-mediated thrombocytopenia among important risks.
- Hypoglycemia risk can rise with certain other diabetes medicines.
- Parkinson trials add tolerability demands without an established neurologic benefit.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Strong human evidence for approved usesEvidence is strong for labeled diabetes uses. For Parkinson disease, the best current evidence is a negative multicenter Phase 3 trial that outweighs the earlier small positive signal.
Selected research to read
Small controlled study that generated the disease-modification hypothesis.
Larger multicenter trial finding no benefit on the primary motor endpoint.
FDA approval & research status
FDA-approved exenatide products have specific type 2 diabetes indications. No exenatide product is FDA approved for Parkinson disease, cognition, or neuroprotection.
Approved uses covered here
- Improving glycemic control in adults with type 2 diabetes under product-specific FDA labeling
FDA approved for type 2 diabetes products
Exenatide is approved under product-specific diabetes labeling. Parkinson's and other investigational uses remain separate from that approval.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- Whether another GLP-1 molecule can produce a reproducible Parkinson benefit
- Which pharmacologic or trial-design differences explain conflicting results
- Whether any biomarker identifies a neurologic responder subgroup
- Long-term brain effects outside diabetes
The takeaway
Exenatide is a proven diabetes peptide and a negative Parkinson Phase 3 result. That failure is scientifically useful—and a strong warning against treating early signals as settled benefit.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1fdaFDA prescribing information: Byetta
Current diabetes indication, warnings, adverse reactions, and product-specific evidence.
- 2pubmedEarlier randomized exenatide Parkinson trial
Small controlled study that generated the disease-modification hypothesis.
- 3pubmedNegative Phase 3 exenatide Parkinson trial
Larger multicenter trial finding no benefit on the primary motor endpoint.